Improving mobility after revascularization in peripheral artery disease: the impact pad trial - more than 300,000 surgical or endovascular lower extremity revascularization procedures are performed…

Active Cooperative Agreement Awarded Last action

Award ID
UH3HL169565
Recipient
Awarding agency
Obligated
$1,432,256

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date 30% complete
Place of performance
Illinois, USA

Award details come from USAspending.gov.

Description

Improving mobility after revascularization in peripheral artery disease: the impact pad trial - more than 300,000 surgical or endovascular lower extremity revascularization procedures are performed annually for medicare beneficiaries who have lower extremity peripheral artery disease (pad) without limb threatening ischemia, and rates of these procedures are increasing. In these patients, revascularization typically improves, but does not eliminate, pad related walking impairment. Lower extremity revascularization combined with supervised exercise significantly improves walking performance compared to revascularization alone in people who have pad without limb threatening ischemia. However, supervised exercise is inaccessible or burdensome for most pad patients. We hypothesize that home-based exercise combined with lower extremity revascularization will significantly improve walking performance compared to revascularization alone in patients with pad undergoing revascularization for disabling pad. We further hypothesize that inorganic nitrate, a major source of nitric oxide (no) abundant in beetroot juice, will improve walking performance after lower extremity revascularization, compared to placebo. In preclinical models, no inhibits inflammation, neointimal hyperplasia, thrombosis, and vascular smooth muscle cell migration at sites of revascularization. No increases angiogenesis and perfusion, repairs skeletal muscle damaged by ischemia, and stimulates mitochondrial activity. A large body of evidence, assembled over more than 25 years, supports our hypothesis that inorganic nitrate (such as that in nitrate-rich beetroot juice) will improve walking performance and other lower extremity outcomes after lower extremity revascularization. Effective, accessible, and safe therapies are needed to enhance the benefits and improve durability of lower extremity revascularization. Therefore, in a randomized clinical trial with a 2 X 2 factorial design, we will test the following two primary hypotheses in 386 patients randomized within three months of a successful lower extremity revascularization for disabling pad: first, that home-based exercise combined with lower extremity revascularization will improve six-minute walk distance more than revascularization alone at 6-month follow-up (primary aim #1). Second, that nitrate-rich beetroot juice combined with lower extremity revascularization will improve six-minute walk, compared to placebo combined with revascularization at 6-month follow-up (primary aim #2). In secondary aims, we will establish whether home-based exercise, compared to control, and whether nitrate-rich beetroot juice, compared to placebo, improve the walking impairment questionnaire and the promis mobility questionnaire and prevent hemodynamic failure of the revascularized vessel. In exploratory aims, we will test the effects of the interventions on plasma nitric oxide bioavailability and on gastrocnemius muscle biopsy measures of capillary density, myofiber size, and mitochondrial activity. If our hypotheses are correct, results of this trial will have a major impact on improving mobility in the large and growing number of people undergoing revascularization for disabling pad.

Subawards

Subrecipient Amount Awarded
Emory University IMProving mobility After revasCularizaTion in Peripheral Artery Disease: the IMPACT PAD Trial $36,901
Michigan State University $40,542
University Of South Florida $30,987
Rancho Research Institute $37,376
Wake Forest University $49,296
University Of Arizona $52,465
Dartmouth-Hitchcock Clinic $129,450

Quick answers

Who received award UH3HL169565?

UH3HL169565 was awarded to Northwestern University by National Heart Lung and Blood Institute (National Institutes of Health) on September 17, 2024.

How much is award UH3HL169565 worth?

$1,432,256 has been obligated on UH3HL169565.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award